Screen Shot 2020-11-06 at 11.50.02 am.pn

ADVANCED

RAGE Biotech is developing novel therapeutics targeting the Receptor for Advanced Glycation End-products (RAGE) for patients with difficult-to-treat inflammatory disease.

 
1594021978465.jpeg

IN INFLAMMATION, RAGE MATTERS

RAGE is an important therapeutic target in a wide range of inflammatory diseases.

RAGE is a 'sensing receptor' that recognises a large number of potential triggers.

This makes it difficult to develop a drug to RAGE using traditional approaches.

At RAGE Biotech, we are harnessing cutting edge RNA-targeting and therapeutic peptide technologies to bring an effective RAGE inhibitor to the clinic.


Our aim is to improve the lives of people with chronic inflammatory conditions around the world. 

 
 
Doctor High Five_edited.jpg

MEDIA & PRESS UPDATES

 

RAGE BIOTECH RAISES $3.7 MILLION IN SEED ROUND LED BY IP GROUP

9 November, 2021

RAGE Biotech, a university spin-out developing novel therapies to treat inflammatory diseases, has raised $3.7 million in funding to advance its breakthrough drug to clinical trials, with the potential to benefit more than 300 million people worldwide.
IP Group led the investment round, with support from Monash Investment Holdings (MIH).
The company has also announced the appointment of experienced pharmaceutical start-up leader Christopher Wraight as CEO and Director.
RAGE Biotech is commercialising inhibitors of the Receptor for Advanced Glycation End- products (RAGE), an important therapeutic target in a wide range of inflammatory diseases.
Founded on intellectual property co-developed by leading researchers from Monash University, The University of Western Australia, Murdoch University and the Baker and Perron Institutes, RAGE Biotech has world-wide exclusive technology licences to inhibitors of RAGE.
The most advanced drug is an RNA therapeutic, a splice-switching oligonucleotide (SSO), which the company is currently developing as an inhaled drug to target lung diseases where inflammation and scarring are a problem.
The breakthrough drug has the potential to improve the lives of patients globally who are suffering from chronic inflammatory lung diseases. This $3.7 million investment brings it one step closer to the clinic.

TACKLING INFLAMMATORY LUNG DISEASE

15 July, 2020

A new spin-out company will develop new therapies designed to help patients with chronic inflammatory lung diseases such as severe asthma, cystic fibrosis and chronic obstructive pulmonary disease (COPD).

Globally, COPD is the fourth leading cause of mortality and morbidity, with chronic inflammation being a key feature and driver of disease progression in COPD, cystic fibrosis and severe asthma.

RAGE Biotech is developing new approaches to modulate the receptor for advanced glycation end-products (RAGE), an important target in chronic inflammation with links to COPD and cystic fibrosis.

The company is founded on intellectual property co-developed by leading researchers from Monash University, The University of Western Australia, Harry Perkins Institute of Medical Research, Murdoch University and the Baker Institute, licensed to RAGE Biotech by Monash Innovation.

The breakthrough discoveries were led by endocrinology expert Professor Merlin Thomas of the Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, in collaboration with Professor Kevin Pfleger, a laboratory head at Harry Perkins Institute of Medical Research and UWA Professor and Professor Steve Wilton of Murdoch University.

AUSTRALIAN UNIVERSITIES JOIN FORCES TO TACKLE INFLAMMATORY LUNG DISEASE

8 July, 2020

A new spin-out company, RAGE Biotech, will develop novel therapies designed to help patients with chronic inflammatory lung diseases such as severe asthma, cystic fibrosis and chronic obstructive pulmonary disease (COPD), supported by investment from IP Group, Monash University (Monash) and The University of Western Australia (UWA).

Globally, COPD is the fourth leading cause of mortality and morbidity, with chronic inflammation being a key feature and driver of disease progression in COPD, cystic fibrosis and severe asthma.


RAGE Biotech is developing new approaches to modulate the receptor for advanced glycation end-products (RAGE), an important target in chronic inflammation with links to COPD and cystic fibrosis.

DIABETES FUNDING GROUP WELCOMES LAUNCH OF NEW BIOTECH COMPANY

8 July, 2020

WA’s peak diabetes research funding group has welcomed the creation of a new biotech company that could help fast-track fresh therapies to reduce the health complications of diabetes.

Supported by investment from IP Group, Monash University (Monash) and The University of Western Australia (UWA), the company – RAGE Biotech – is developing new approaches to modulate the Receptor for Advanced Glycation End-products (RAGE).  Activation of RAGE contributes to the development of diabetes and its complications. New therapeutics blocking RAGE are therefore likely to prove significant for the prevention and treatment of diabetes.


Diabetes Research WA Executive Director Sherl Westlund welcomed RAGE Biotech’s arrival.  “This is wonderful progress and very exciting given that Diabetes Research WA has channelled $60,000 into the work of UWA Professor Kevin Pfleger, who is looking at how to inhibit RAGE triggering signalling in cells that leads to inflammation and cell injury,” she said.

CONTACT US

RAGE Biotech Pty Ltd
ACN 640 194 770
40 City Road, Southbank, Victoria 3006, Australia

Thanks for submitting!